


RFK Jr. Calls for Comprehensive Review of Mifepristone Amid Safety Concerns
Health Secretary Robert F. Kennedy Jr. requests FDA review of mifepristone following alarming safety report indicating higher risks than previously reported.
Overview
During a Senate committee hearing, Health Secretary Robert F. Kennedy Jr. announced a request for the FDA to review mifepristone, after a new study revealed that more than 10% of women face serious health risks post-ingestion, significantly higher than the FDA's reported 0.5%. This review, viewed positively by pro-life advocates, raises concerns over abortion access and women's safety. Kennedy's actions reflect a broader political push to reassess abortion medication regulations, with critics warning of potential dangers stemming from politicizing medical decisions.
Content generated by AI—learn more or report issue.

Get both sides in 5 minutes with our daily newsletter.
Analysis
Analysis unavailable for this viewpoint.
Articles (3)



FAQ
No FAQs available for this story.
History
- This story does not have any previous versions.